Request / Find a Test Tool

The National Genomic Test Directories specify which genomic tests are commissioned by the NHS in England, to be delivered by Genomic Laboratory Hubs.

This tool allows clinical teams to search all of the genomic tests available to patients through the National Testing Directory. From here you can find out more details about each test and information about how to order them. These tests can only be ordered by clinical teams, if you are a patient looking to request a test please speak to your clinical team directly.

Endocrine neoplasia

Clinical Indication ID & Name

R217

Endocrine neoplasia

Test Group

Endocrinology

Test code

R217.1

Test name

N/A

Target genes

Endocrine neoplasms (648)

Test scope

n/a

Test method/ technology

Small panel

Optimal Family Structure

n/a

Eligibility Criteria

Testing of individual (proband) affected with endocrine abnormalities where the individual +/- family history meets one of the following criteria:
1. Multiple endocrine neoplasia type 1 (MEN1). The proband has:
a. Parathyroid multiglandular disease (hyperplasia/ adenomas) (<35 years), OR b. Any pituitary adenoma or insulinoma (< 20years), OR c. Pituitary macroadenoma (<30 years), OR d. ≥2 MEN1-related endocrine abnormalities (any age), OR e. ≥1 MEN1-related endocrine abnormality and ≥1 MEN1-related non-endocrine tumours (any age), OR f. ≥1 MEN1-related endocrine abnormality and a first degree relative has ≥1 MEN1-related endocrine abnormality MEN1-related endocrine abnormalities include: - Parathyroid hyperplasia/multiglandular adenomas - Pituitary tumors - Endocrine tumors of the gastro-entero-pancreatic (GEP) tract - Carcinoid tumors - Adrenocortical tumors MEN1-related non-endocrine tumours include: - facial angiofibromas - collagenomas - meningioma 2. Familial isolated pituitary adenoma (FIPA) • Isolated pituitary adenoma developing under the age of 35, with at least one first degree relative with an isolated pituitary adenoma 3. X-linked acrogigantism • Onset of excess of growth hormone diagnosed by age 20 years in male patients, with increased growth velocity and/or tall stature (height >2 standard deviations above the mean, or >3 standard deviations over mid-parental height)

• If testing on blood is negative and clinical suspicion of this diagnosis is strong, please contact the testing laboratory to discuss sending a fresh frozen tissue or skin biopsy sample to identify a mosaic form of the condition

Where a patient doesn’t meet the stated criteria but there is strong clinical suspicion of a monogenic predisposition to endocrine neoplasia, testing can go ahead after discussion in a specialist MDT meeting

Test code

R217.2

Test name

N/A

Target genes

MEN1;AIP;CDKN1B;CDC73

Test scope

n/a

Test method/ technology

MLPA or equivalent

Optimal Family Structure

n/a

Eligibility Criteria

Testing of individual (proband) affected with endocrine abnormalities where the individual +/- family history meets one of the following criteria:
1. Multiple endocrine neoplasia type 1 (MEN1). The proband has:
a. Parathyroid multiglandular disease (hyperplasia/ adenomas) (<35 years), OR b. Any pituitary adenoma or insulinoma (< 20years), OR c. Pituitary macroadenoma (<30 years), OR d. ≥2 MEN1-related endocrine abnormalities (any age), OR e. ≥1 MEN1-related endocrine abnormality and ≥1 MEN1-related non-endocrine tumours (any age), OR f. ≥1 MEN1-related endocrine abnormality and a first degree relative has ≥1 MEN1-related endocrine abnormality MEN1-related endocrine abnormalities include: - Parathyroid hyperplasia/multiglandular adenomas - Pituitary tumors - Endocrine tumors of the gastro-entero-pancreatic (GEP) tract - Carcinoid tumors - Adrenocortical tumors MEN1-related non-endocrine tumours include: - facial angiofibromas - collagenomas - meningioma 2. Familial isolated pituitary adenoma (FIPA) • Isolated pituitary adenoma developing under the age of 35, with at least one first degree relative with an isolated pituitary adenoma 3. X-linked acrogigantism • Onset of excess of growth hormone diagnosed by age 20 years in male patients, with increased growth velocity and/or tall stature (height >2 standard deviations above the mean, or >3 standard deviations over mid-parental height)

• If testing on blood is negative and clinical suspicion of this diagnosis is strong, please contact the testing laboratory to discuss sending a fresh frozen tissue or skin biopsy sample to identify a mosaic form of the condition

Where a patient doesn’t meet the stated criteria but there is strong clinical suspicion of a monogenic predisposition to endocrine neoplasia, testing can go ahead after discussion in a specialist MDT meeting

Commissioning group

Specialised

Overlapping idications

n/a

Address for samples/request forms

North Thames GLH, Rare & Inherited Disease Genomic Laboratory
Specimen Reception, Level 5 Barclay House, 37 Queen Square,
London WC1N 3BH

Contact with queries

gos-tr.norththamesgenomics@nhs.net

Supporting documents

Rare Disese WGS Clinician pack

Education resources

n/a

Service updates

n/a

Request form download

Consent record

See consent guidance in test request form

Sample requirements

See sample guidance in test request form